Krystal Biotech, Inc.
No SEC Form 4 filings for $KRYS in the last 30 days.
See all $KRYS insider activity →Simply Wall St reports Krystal Biotech (KRYS) Q2 2026 results: net income rose to $54.77M from $38.33M, with basic EPS from continuing ops at $1.85 and diluted EPS at $1.79. First-half 2026 net income was $110.70M. The piece links profitability to VYJUVEK demand and concentration risk.
Stocks settled sharply higher as Middle East tensions eased. The article cites a 66% chance of a +25 bp FOMC hike (Sept 15-16) and an 88% chance of an ECB +25 bp hike (Sept 10). WTI fell over 5%, lifting 10-year Treasuries and lowering yields. It also lists major movers including META (+6%), ORCL (+9%), and ATKR (+28%) after a $3.8B deal.
Markets were mixed as investors priced a 63% chance of a 25 bp FOMC hike on Sept. 15-16. U.S. 10-year yields fell to 4.688% and German bunds and UK gilts moved lower. Airline and cruise stocks rose as WTI dropped over 6%. Software gained, while semiconductors and energy fell. Notable movers included ATKR (+28%) on a $3.8B Prysmian deal and CNH (+16%) raising EPS guidance.
Over the past 7 days, alphai's AI scored 9 news stories mentioning KRYS (Krystal Biotech, Inc.). Coverage has skewed bearish: 2 bullish, 1 neutral, and 6 bearish.
Recent KRYS coverage spans earnings, market movers and macro economy.
Stronger profitability supports the bull case for VYJUVEK demand, but the article flags ongoing concentration and reimbursement-driven volatility risk.
Earnings miss on a specific revenue line is a direct negative catalyst for KRYS.
A revenue miss is a direct earnings datapoint likely to weigh on valuation and sentiment.
Earnings-related revenue miss is a direct fundamental negative catalyst.
Near-term trading is driven by the gap between strong year-over-year VYJUVEK growth and expectations for faster sequential commercial acceleration.
alphai scores every news story that mentions KRYS with an AI model for sentiment and relevance, and aggregates insider trades from Krystal Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St reports Krystal Biotech (KRYS) Q2 2026 results: net income rose to $54.77M from $38.33M, with basic EPS from continuing ops at $1.85 and diluted EPS at $1.79. First-half 2026 net income was $110.70M. The piece links profitability to VYJUVEK demand and concentration risk.
6 min readStocks settled sharply higher as Middle East tensions eased. The article cites a 66% chance of a +25 bp FOMC hike (Sept 15-16) and an 88% chance of an ECB +25 bp hike (Sept 10). WTI fell over 5%, lifting 10-year Treasuries and lowering yields. It also lists major movers including META (+6%), ORCL (+9%), and ATKR (+28%) after a $3.8B deal.
6 min readMarkets were mixed as investors priced a 63% chance of a 25 bp FOMC hike on Sept. 15-16. U.S. 10-year yields fell to 4.688% and German bunds and UK gilts moved lower. Airline and cruise stocks rose as WTI dropped over 6%. Software gained, while semiconductors and energy fell. Notable movers included ATKR (+28%) on a $3.8B Prysmian deal and CNH (+16%) raising EPS guidance.
7 min readMarkets rose as investors priced in easing geopolitical risks and US economic strength. The article cites a 63% chance of a +25 bp FOMC hike and notes US 10-year yields fell to 4.682%. It highlights stock moves including Meta (+5%), Amazon (+4%), and ATKR surging after Prysmian agreed to buy for $3.8B.
7 min readKrystal Biotech (KB) shares fell more than 10% after Q2 results. The company reported $119.2M global net product revenue from VYJUVEK, up 24% year over year, with cumulative revenue of $965.9M and 95% gross margin. Net income was $54.8M ($1.85 basic EPS). Cash totaled $1.1B. Investors focused on U.S. uptake and international reimbursement timing.
5 min readUS stock index futures rose in premarket as oil fell and bond yields eased, helped by reports of US-Iran talks. S&P futures were up 0.5% and Nasdaq up 0.4%, with Mag 7 mostly higher. Notable movers included ATKR +27% on Prysmian’s $95/share bid, BMY +5% on AstraZeneca acquisition talks, and SRAD -14% after guidance cut.
7 min readKrystal Biotech (KRYS) shares fell about 6% in pre-open after it reported Q2 2026 results. The company posted $119.2M in global VYJUVEK net revenue, up 24% year over year but below analyst consensus near $126M. Gross margin was 95% and prescribers rose above 640, but the revenue miss drove selling.
2 min readKrystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26-ex991xpressrelease.htm EX-99.1 Document Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launch
6 min readUS stock index futures rose ahead of Monday’s open, with Nasdaq Composite futures up about 0.82% to ~28,636, Dow futures up about 0.46% to ~52,875, and S&P 500 futures up about 0.50% to ~7,557.75. Investors await a busy earnings week including Berkshire Hathaway and Palantir, while crude oil fell 5-6% after Trump said US-Iran peace talks would resume.
6 min readThe article says U.S. healthcare stocks have held up in 2025 and highlights Krystal Biotech (KRYS), Exelixis (EXEL), and CVS Health (CVS) as outperformers. KRYS is driven by Vyjuvek and new approvals in Europe and Japan. EXEL’s focus is zanzalintinib for metastatic colorectal cancer. CVS cites health-insurance cost controls and a GLP-1 access platform. Market caps and gross margins are cited.
6 min read
